DE60205455T2 - Naphthyridinderivate - Google Patents

Naphthyridinderivate Download PDF

Info

Publication number
DE60205455T2
DE60205455T2 DE60205455T DE60205455T DE60205455T2 DE 60205455 T2 DE60205455 T2 DE 60205455T2 DE 60205455 T DE60205455 T DE 60205455T DE 60205455 T DE60205455 T DE 60205455T DE 60205455 T2 DE60205455 T2 DE 60205455T2
Authority
DE
Germany
Prior art keywords
custom
character
tif
therapy
naphthyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60205455T
Other languages
English (en)
Other versions
DE60205455D1 (de
Inventor
Francoise J Gellibert
Charles D Hartley
Neil Mathews
James M Woolven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE60205455D1 publication Critical patent/DE60205455D1/de
Application granted granted Critical
Publication of DE60205455T2 publication Critical patent/DE60205455T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60205455T 2001-02-02 2002-01-30 Naphthyridinderivate Expired - Fee Related DE60205455T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0102672.3A GB0102672D0 (en) 2001-02-02 2001-02-02 Compounds
PCT/EP2002/000939 WO2002062794A2 (en) 2001-02-02 2002-01-30 Compounds

Publications (2)

Publication Number Publication Date
DE60205455D1 DE60205455D1 (de) 2005-09-15
DE60205455T2 true DE60205455T2 (de) 2006-06-14

Family

ID=9908018

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60205455T Expired - Fee Related DE60205455T2 (de) 2001-02-02 2002-01-30 Naphthyridinderivate

Country Status (7)

Country Link
US (1) US20040063949A1 (de)
EP (1) EP1358187B1 (de)
JP (1) JP2004523541A (de)
AT (1) ATE301654T1 (de)
DE (1) DE60205455T2 (de)
GB (1) GB0102672D0 (de)
WO (1) WO2002062794A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
CA2494367A1 (en) * 2002-07-25 2004-02-05 Scios Inc. Methods for improvement of lung function using tgf-.beta. inhibitors
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
EP1543001B1 (de) * 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
CA2498047C (en) 2002-09-18 2009-05-19 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
CA2499429C (en) 2002-09-18 2010-09-21 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
PL375974A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
CA2496295C (en) 2002-09-18 2010-11-23 Michael John Munchhof Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
EA200500286A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
AU2003291642A1 (en) * 2002-11-22 2004-06-18 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
WO2004050659A1 (en) * 2002-11-27 2004-06-17 Eli Lilly And Company Novel compounds as pharmaceutical agents
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
ES2647472T3 (es) 2006-10-03 2017-12-21 Genzyme Corporation Anticuerpos contra TGF-BETA para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
ES2559521T3 (es) * 2006-10-16 2016-02-12 Thesan Pharmaceuticals, Inc. Pirazolil tienopiridinas terapéuticas
EP2737083A1 (de) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Verfahren zur diagnose und behandlung des myhre-syndroms
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
AU2017235461B2 (en) 2016-03-15 2023-02-23 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10760057B2 (en) 2017-07-06 2020-09-01 Wisconsin Alumni Research Foundation Human pluripotent stem cell-based screening for smooth muscle cell differentiation and disease
EP3768320A1 (de) * 2018-03-23 2021-01-27 Cytoo Alk5-inhibitoren als skelettmuskelhypertrophieverursacher
WO2020123453A2 (en) * 2018-12-11 2020-06-18 Theravance Biopharma R&D Ip, Llc Alk5 inhibitors
EP3947737A2 (de) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage und vorbeugung von krebs bei patienten mit prämalignen läsionen
EP4061809A1 (de) * 2019-11-22 2022-09-28 Theravance Biopharma R&D IP, LLC Substituierte 1,5-naphthyridine oder chinoline als alk5-inhibitoren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60001229T2 (de) * 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
EP1178981B1 (de) * 1999-05-14 2003-06-25 Ortho-Mcneil Pharmaceutical, Inc. Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung

Also Published As

Publication number Publication date
DE60205455D1 (de) 2005-09-15
JP2004523541A (ja) 2004-08-05
WO2002062794A2 (en) 2002-08-15
US20040063949A1 (en) 2004-04-01
ATE301654T1 (de) 2005-08-15
EP1358187B1 (de) 2005-08-10
EP1358187A2 (de) 2003-11-05
WO2002062794A3 (en) 2002-10-03
GB0102672D0 (en) 2001-03-21

Similar Documents

Publication Publication Date Title
ATE301654T1 (de) Naphthyridinderivate
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
DE602004011394D1 (en) Thiazolderivate
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
SE9902987D0 (sv) Novel compounds
ATE248837T1 (de) Chinuclidin-acrylamide
PL367682A1 (en) Dolastatin 10 derivatives
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
PL367814A1 (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
CA2498047A1 (en) Novel imidazole compounds as transforming growth factor (tgf) inhibitors
GB0112348D0 (en) Compounds
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
SE9903997D0 (sv) New compounds
SE0102440D0 (sv) New compound
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
SE0302756D0 (sv) Novel Compounds
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
MXPA04005809A (es) Inhibidores de proteinas quinasas.
AU2003245989A1 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
SE0102639D0 (sv) Novel compounds
SE0103325D0 (sv) Novel compounds
SE0202280D0 (sv) Novel compounds
SE0300907D0 (sv) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee